ARCT
Price
$13.95
Change
+$0.54 (+4.03%)
Updated
Jun 25, 04:59 PM (EDT)
Capitalization
378.33M
46 days until earnings call
CBUS
Price
$1.60
Change
+$0.04 (+2.56%)
Updated
Jun 25, 04:59 PM (EDT)
Capitalization
77.42M
Interact to see
Advertisement

ARCT vs CBUS

Header iconARCT vs CBUS Comparison
Open Charts ARCT vs CBUSBanner chart's image
Arcturus Therapeutics Holdings
Price$13.95
Change+$0.54 (+4.03%)
Volume$4.66K
Capitalization378.33M
Cibus
Price$1.60
Change+$0.04 (+2.56%)
Volume$12.67K
Capitalization77.42M
ARCT vs CBUS Comparison Chart in %
Loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CBUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARCT vs. CBUS commentary
Jun 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a StrongBuy and CBUS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 26, 2025
Stock price -- (ARCT: $13.95 vs. CBUS: $1.56)
Brand notoriety: ARCT and CBUS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 114% vs. CBUS: 144%
Market capitalization -- ARCT: $378.33M vs. CBUS: $77.42M
ARCT [@Biotechnology] is valued at $378.33M. CBUS’s [@Biotechnology] market capitalization is $77.42M. The market cap for tickers in the [@Biotechnology] industry ranges from $312.97B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whileCBUS’s FA Score has 0 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • CBUS’s FA Score: 0 green, 5 red.
According to our system of comparison, ARCT is a better buy in the long-term than CBUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 7 TA indicator(s) are bullish while CBUS’s TA Score has 5 bullish TA indicator(s).

  • ARCT’s TA Score: 7 bullish, 2 bearish.
  • CBUS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ARCT is a better buy in the short-term than CBUS.

Price Growth

ARCT (@Biotechnology) experienced а +12.96% price change this week, while CBUS (@Biotechnology) price change was +7.59% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.95%. For the same industry, the average monthly price growth was +31.79%, and the average quarterly price growth was +15.79%.

Reported Earning Dates

ARCT is expected to report earnings on Aug 11, 2025.

CBUS is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (+1.95% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARCT($378M) has a higher market cap than CBUS($77.4M). ARCT YTD gains are higher at: -17.796 vs. CBUS (-43.885). ARCT has higher annual earnings (EBITDA): -63.92M vs. CBUS (-264.18M). ARCT has more cash in the bank: 217M vs. CBUS (23.6M). CBUS has less debt than ARCT: CBUS (35.6M) vs ARCT (42.7M). ARCT has higher revenues than CBUS: ARCT (131M) vs CBUS (4.75M).
ARCTCBUSARCT / CBUS
Capitalization378M77.4M488%
EBITDA-63.92M-264.18M24%
Gain YTD-17.796-43.88541%
P/E RatioN/AN/A-
Revenue131M4.75M2,757%
Total Cash217M23.6M919%
Total Debt42.7M35.6M120%
FUNDAMENTALS RATINGS
ARCT vs CBUS: Fundamental Ratings
ARCT
CBUS
OUTLOOK RATING
1..100
742
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
50
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6396
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARCT's Valuation (50) in the Pharmaceuticals Major industry is in the same range as CBUS (50) in the null industry. This means that ARCT’s stock grew similarly to CBUS’s over the last 12 months.

ARCT's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as CBUS (100) in the null industry. This means that ARCT’s stock grew similarly to CBUS’s over the last 12 months.

ARCT's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as CBUS (100) in the null industry. This means that ARCT’s stock grew similarly to CBUS’s over the last 12 months.

ARCT's Price Growth Rating (63) in the Pharmaceuticals Major industry is somewhat better than the same rating for CBUS (96) in the null industry. This means that ARCT’s stock grew somewhat faster than CBUS’s over the last 12 months.

ARCT's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as CBUS (100) in the null industry. This means that ARCT’s stock grew similarly to CBUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTCBUS
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 21 days ago
87%
Bearish Trend 15 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CBUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IEGAX23.47N/A
N/A
Invesco EQV Intl Small Company A
SCUVX27.14N/A
N/A
Hartford Schroders US Small Cap Opps A
LGLQX47.46N/A
N/A
Lord Abbett Growth Leaders R2
FGHMX115.22N/A
N/A
Fidelity Advisor Communication ServicesC
EMSLX18.67N/A
N/A
Shelton Emerging Markets Investor

CBUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CBUS has been loosely correlated with ARCT. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if CBUS jumps, then ARCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CBUS
1D Price
Change %
CBUS100%
+3.31%
ARCT - CBUS
41%
Loosely correlated
+7.19%
ABOS - CBUS
39%
Loosely correlated
+2.44%
CRBU - CBUS
37%
Loosely correlated
+6.82%
FHTX - CBUS
36%
Loosely correlated
-0.41%
HOWL - CBUS
35%
Loosely correlated
N/A
More